Melatonin treatment in LNCaP prostate cancer cells inhibited IL-6 upregulation and suppressed the NFκB-mediated upregulation of AR-V7 demonstrating how the indolamine can impede AR-V7-mediated carcinogenesis and downregulate the receptor variant entirely. The gene discussed is NFKB1; the disease is Familial prostate cancer.